Joint Symposium 15
Oncology & Theranostics Committee / European Haematology Association (EHA)
Accessible on-demand at any time

Session Title
Imaging Challenges in Multiple Myeloma - Quo Vadis 2021?

Chairperson
Cristina Nanni (Bologna, Italy)

Programme
29 min  Françoise Kraeber-Bodéré (Nantes, France): Therapy Assessment with FDG
29 min  Frédéric Lecouvet (Louvain, Belgium): WB-MRI - My Favourite!
29 min  Constantin Lapa (Augsburg, Germany): Update in Non FDG
3 min  Session Summary by Chairperson

Educational Objectives
1. To learn about therapy assessment with FDG PET/CT
2. To have a new insight into WB-MRI in MM
3. To understand new radiolabelled compounds useful in MM and possible therapeutical options with radionuclides

Summary
FDG PET/CT is recommended by the International Myeloma Working Group (IMWG) as an useful procedure to stratify patients with different outcomes at different time points. It is becoming clearer and clearer that its strength relies especially on therapy assessment: FDG PET/CT is, in fact, able to recognize areas of minimal residual disease, integrating the clinical definition of complete responders. The great performance of FDG PET/CT is empowered by new tracers, that can improve its sensitivity and can drive the possibility of radio-metabolic treatments. In the clinical practice FDG PET/CT is associated to MRI. Recent technological advances have produced MR tomographs capable of fast acquisitions throughout the entire body providing also DWI sequences.

This session will give an overview on the state of the art of FDG PET/CT, new tracers and WB-MRI in MM.

Key Words
PET/CT, Multiple Myeloma, WB-MRI, Non FDG compounds